RKDA Earnings
Arcadia Biosciences Inc
$
4.630
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Arcadia Biosciences Inc(RKDA) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Arcadia Biosciences Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2024Q4 | 2025-03-20 | After Hours | -0.89 | -2.98 | -234.83 | 1.15M | 1.22M | +5.74 | -4.55 | +2.84 |
| FY2024Q2 | 2024-08-13 | After Hours | 1.27 | 0.78 | -38.58 | 925.00K | 1.31M | +41.19 | -11.04 | -11.00 |
| FY2024Q1 | 2024-05-09 | - | -2.52 | -1.78 | +29.37 | 1.19M | 1.26M | +5.15 | +4.85 | +46.46 |
| FY2023Q4 | 2024-03-28 | - | -2.68 | -2.48 | +7.46 | 1.75M | 1.17M | -32.97 | -3.91 | -9.13 |
| FY2023Q3 | 2023-11-09 | - | -2.67 | -1.83 | +31.46 | 1.55M | 1.60M | +3.33 | -2.99 | -8.06 |
| FY2023Q2 | 2023-08-10 | - | -4.92 | -2.64 | +46.34 | 1.59M | 1.39M | -12.64 | +0.45 | -3.02 |
| - | 2023-05-15 | - | -6.35 | -3.83 | +39.69 | - | - | - | -4.47 | -10.12 |
| - | 2022-11-10 | - | -0.19 | -0.12 | +36.84 | - | - | - | +5.48 | +4.52 |
| - | 2022-08-11 | - | -0.31 | -0.17 | +45.16 | - | - | - | +3.26 | +4.35 |
| - | 2022-05-12 | - | -0.31 | -0.21 | +32.26 | - | - | - | +2.04 | +65.67 |
RKDA Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Arcadia Biosciences Inc reported performance for FY2024Q4, announced on 2025-03-20. The company achieved an EPS of -2.98, compared to analyst estimates of -0.89 by -234.83% . Revenue for the quarter reached 1.22M compared to expectations of 1.15M by 5.74% .
The stock price reacted with a -4.55% one-day change and a 2.84% five-day change following the earnings release. These movements reflect market reaction in Arcadia Biosciences Inc growth trajectory and strategic initiatives.
RKDA Earnings Forecast
Looking ahead, Arcadia Biosciences Inc(RKDA) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 1.60M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming , revenue estimates have been adjusted Go Up by 19.37% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Arcadia Biosciences Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between RKDA's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q2 2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+19.37%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:6.40M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price4.63
RKDA Revenue and EPS Performance: A Historical Perspective
Arcadia Biosciences Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q4 (2025-03-20,After Hours):
EPS: -2.98 (Actual) vs.-0.89 (Estimate) (-234.83%)
Revenue: 1.22M (Actual) vs. 1.15M (Estimate) (5.74%)
Price Reaction: -4.55%(1-Day), 2.84%(5-Day)
FY2024Q2 (2024-08-13,After Hours):
EPS: 0.78 (Actual) vs.1.27 (Estimate) (-38.58%)
Revenue: 1.31M (Actual) vs. 925.00K (Estimate) (41.19%)
Price Reaction: -11.04%(1-Day), -11.00%(5-Day)
FY2024Q1 (2024-05-09,):
EPS: -1.78 (Actual) vs.-2.52 (Estimate) (29.37%)
Revenue: 1.26M (Actual) vs. 1.19M (Estimate) (5.15%)
Price Reaction: 4.85%(1-Day), 46.46%(5-Day)
Earnings Reaction
The chart below shows how RKDA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RKDA sees a +5.02% change in stock price 10 days leading up to the earnings, and a +1.30% change 10 days following the report. On the earnings day itself, the stock moves by +0.31%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in DEC/2024, the stock changed -4.55% on the day following the earnings release and then changed by -15.15% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Arcadia Biosciences Inc (RKDA) Q1 2025 Earnings Call Summary
Neutral
2025-05-08
The earnings call presents a mixed picture. While the Zola brand shows strong sales growth and distribution expansion, gross margins are declining, and the company is transitioning to a single product line. Although the cash position is healthy, regulatory issues and unclear management responses in the Q&A create uncertainty. The revenue guidance is stable but not growing, and the completion of a key transaction is delayed. These factors suggest a neutral stock price movement in the near term.
Arcadia Biosciences Inc (RKDA) Q4 2024 Earnings Call Summary
Negative
2025-03-22
Despite strong Zola sales growth and distribution expansion, the company faces significant challenges such as missing EPS expectations, declining cash reserves, and increased SG&A expenses. The lack of forward guidance and unclear management responses in the Q&A further add to investor uncertainty. The pending transaction with Roosevelt Resources and the decline in GLA oil sales also pose risks. These factors are likely to result in a negative stock price movement.
Arcadia Biosciences, Inc. (RKDA) Q3 2024 Earnings Call Summary
Neutral
2024-11-12
The earnings call presents a mixed picture. The company shows strong Zola sales growth and cost reduction initiatives, but faces challenges like lack of forward guidance and distribution uncertainties. While there's no shareholder return plan, the financials indicate cost increases and cash flow concerns. The Q&A session reveals some confidence in infrastructure but lacks clarity. Without a market cap, the prediction remains neutral as positive growth is offset by risks and uncertainties.
Arcadia Biosciences, Inc. (RKDA) Q2 2024 Earnings Call Summary
Neutral
2024-08-14
The earnings call presents mixed signals: strong Zola sales and high gross margins are positive, but flat total revenues and lack of shareholder return plans are concerning. The Q&A reveals uncertainty about future product launches and market share goals, adding risk. Despite some positive financial metrics, the absence of clear guidance and the presence of competitive pressures and financial risks suggest a neutral stock price movement in the short term.
People Also Watch
FAQ
What were the key highlights of RKDA’s latest earnings report for FY2024Q4?
RKDA reported its FY2024Q4 earnings on 2025-03-20, showcasing a revenue of 1.22M against an estimate of 1.15M, resulting in a 5.74% surprise. The EPS was -2.98, surpassing the expected -0.89 by -234.83% . The stock experienced a -4.55% price change on the earnings day and a 2.84% change over the next five days, reflecting market reactions to the results.
How did RKDA’s stock price react after the FY2024Q4 earnings release?
What are the revenue and EPS estimates for RKDA for 2025/Q2?
How does RKDA’s stock price correlate with earnings forecast revisions?
What should investors expect from RKDA’s next earnings report?